June 30, 2008British Journal of PharmacologyOpen Access

Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea‐pig model

View Full Paper

Ask AI

Bookmark

Population

hERG patch-clamp assay and an anaesthetized guinea-pig model

Design

Preclinical

Authors

XYXiaozhou YaoChina University of Geosciences DAD. L. AndersonIndiana Institute of Technology SRSean RossUniversity of Central Florida

Discussion

Member takes

Implication

Supports guinea-pig hERG QT screening in preclinical development; leaves open direct human translation pending further validation.

Structured PICO

Population

hERG patch-clamp assay and an anaesthetized guinea-pig model

Intervention

16 marketed drugs from various pharmacological classes with a known incidence or lack of QT prolongation in humans

Outcome

QT interval prolongation and hERG inhibitory potencysurrogate

Analysis of hERG inhibitory potency combined with drug exposures and QT interval measurements in anaesthetized guinea-pigs can reliably predict the risk of human QT prolongation during preclinical drug development.

Cite This Study

Yao et al. (2008) studied this question.

synapsesocial.com/papers/6a708900a528af2d65c397fa https://doi.org/10.1038/bjp.2008.267

View Full Paper

Ask AI

Bookmark

Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea‐pig model

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea‐pig model

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider